S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
S&P 500   3,870.29
DOW   31,391.52
QQQ   318.40
Log in

Windtree Therapeutics Stock Forecast, Price & News

-0.09 (-1.79 %)
(As of 03/2/2021 12:00 AM ET)
Today's Range
Now: $4.94
50-Day Range
MA: $5.56
52-Week Range
Now: $4.94
Volume172,789 shs
Average Volume54,282 shs
Market Capitalization$83.59 million
P/E RatioN/A
Dividend YieldN/A
Windtree Therapeutics, Inc., a biotechnology and medical device company, engages in the research and development of products that focus on acute pulmonary and cardiovascular diseases. Its four lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. Windtree Therapeutics, Inc. was incorporated in 1992 and is headquartered in Warrington, Pennsylvania.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Current SymbolNASDAQ:WINT
Phone215 488 9300
Year FoundedN/A



Sales & Book Value

Annual Sales$200,000.00
Book Value$5.48 per share


Net Income$-27,480,000.00


Market Cap$83.59 million
Next Earnings Date4/1/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.95 out of 5 stars

Medical Sector

75th out of 1,969 stocks

Biological Products, Except Diagnostic Industry

7th out of 177 stocks

Analyst Opinion: 3.5Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -
-0.09 (-1.79 %)
(As of 03/2/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive WINT News and Ratings via Email

Sign-up to receive the latest news and ratings for WINT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Windtree Therapeutics (NASDAQ:WINT) Frequently Asked Questions

Is Windtree Therapeutics a buy right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Windtree Therapeutics in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" Windtree Therapeutics stock.
View analyst ratings for Windtree Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Windtree Therapeutics?

Wall Street analysts have given Windtree Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Windtree Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Windtree Therapeutics' next earnings date?

Windtree Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, April 1st 2021.
View our earnings forecast for Windtree Therapeutics

How were Windtree Therapeutics' earnings last quarter?

Windtree Therapeutics, Inc. (NASDAQ:WINT) issued its quarterly earnings results on Monday, November, 16th. The company reported ($0.54) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by $0.05.
View Windtree Therapeutics' earnings history

How has Windtree Therapeutics' stock been impacted by Coronavirus?

Windtree Therapeutics' stock was trading at $3.70 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, WINT shares have increased by 33.5% and is now trading at $4.94.
View which stocks have been most impacted by COVID-19

When did Windtree Therapeutics' stock split? How did Windtree Therapeutics' stock split work?

Windtree Therapeutics's stock reverse split on the morning of Wednesday, April 29th 2020. The 1-3 reverse split was announced on Tuesday, April 28th 2020. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, April 28th 2020. An investor that had 100 shares of Windtree Therapeutics stock prior to the reverse split would have 33 shares after the split.

What price target have analysts set for WINT?

1 analysts have issued 1-year price targets for Windtree Therapeutics' shares. Their forecasts range from $12.25 to $12.25. On average, they anticipate Windtree Therapeutics' share price to reach $12.25 in the next year. This suggests a possible upside of 148.0% from the stock's current price.
View analysts' price targets for Windtree Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Windtree Therapeutics' key executives?

Windtree Therapeutics' management team includes the following people:
  • Mr. Craig E. Fraser, Pres, CEO & Director (Age 56, Pay $686.82k)
  • Dr. Steven G. Simonson, Sr. VP & Chief Medical Officer (Age 62, Pay $535.26k)
  • Mr. John P. Hamill, Sr. VP & CFO (Age 57)
  • Mr. Eric L. Curtis M.B.A., Sr. VP & COO (Age 53)
  • Mr. George Cox, VP of Manufacturing & Supply Chain and Technical Operations (Age 69)
  • Dr. Pratap Paruchuru, Exec. Director of Clinical Devel.
  • Ms. Tracy Rarick, Head of Operations & Program Management
  • Dr. Ronald L. Dundore, Exec. Director of Regulatory Affairs & Quality (Age 66)

Who are some of Windtree Therapeutics' key competitors?

What is Windtree Therapeutics' stock symbol?

Windtree Therapeutics trades on the NASDAQ under the ticker symbol "WINT."

Who are Windtree Therapeutics' major shareholders?

Windtree Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Northern Trust Corp (0.43%) and Paloma Partners Management Co (0.11%). Company insiders that own Windtree Therapeutics stock include Craig Fraser, Eric Curtis, James Huang and John P Hamill.
View institutional ownership trends for Windtree Therapeutics

Which major investors are selling Windtree Therapeutics stock?

WINT stock was sold by a variety of institutional investors in the last quarter, including Paloma Partners Management Co, and Northern Trust Corp.
View insider buying and selling activity for Windtree Therapeutics
or view top insider-selling stocks.

How do I buy shares of Windtree Therapeutics?

Shares of WINT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Windtree Therapeutics' stock price today?

One share of WINT stock can currently be purchased for approximately $4.94.

How much money does Windtree Therapeutics make?

Windtree Therapeutics has a market capitalization of $83.59 million and generates $200,000.00 in revenue each year. The company earns $-27,480,000.00 in net income (profit) each year or ($2.52) on an earnings per share basis.

How many employees does Windtree Therapeutics have?

Windtree Therapeutics employs 31 workers across the globe.

What is Windtree Therapeutics' official website?

The official website for Windtree Therapeutics is www.windtreetx.com.

Where are Windtree Therapeutics' headquarters?

Windtree Therapeutics is headquartered at 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976.

How can I contact Windtree Therapeutics?

Windtree Therapeutics' mailing address is 2600 KELLY ROAD SUITE 100, WARRINGTON PA, 18976. The company can be reached via phone at 215 488 9300 or via email at [email protected]

This page was last updated on 3/3/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.